Table 1.
Patient characteristics.
| Case no. | Age/sex | Malignancy type/stage | Cancer stage | Malignancy treatment before stroke onset | HT | DM | HL | Af | PE/DVT | Prior stroke | Prestroke antithrombotic medication | D-Dimer (μg/ml) at stroke onset | NIHSS on admission | Prestroke mRS | ASPECTS | Site of occlusion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 75/M | Lung squamous carcinoma | III | Chemo-Radiotherapy | + | – | – | – | – | – | None | 29.8 | 20 | 0 | 11 (MRI) | Lt.ICA (C2) |
| 2 | 40/F | Ovarian clear cell adenocarcinoma | III | Surgery | – | – | – | – | + | – | Edoxaban | 21.0 | 18 | 0 | 8 (MRI) | Rt.M1 |
| 3 | 68/F | Colon adenocarcinoma | IV | Surgery, chemotherapy | – | – | – | – | – | – | None | 35.9 | 18 | 2 | 8 (MRI) | Rt.M1 |
| 4 | 61/F | Uterine body cancer | IV | Surgery, chemoradiotherapy | – | – | – | – | – | + | Edoxaban | 21.3 | 15 | 0 | 10 (CT) | Rt.ICA (C1) |
| 5 | 70/M | Lung cancer | IV | None | – | – | – | – | – | – | None | 64.9 | 10 | 0 | 9 (MRI) | Rt.M1 |
| 6 | 72/F | Ovarian adenocarcinoma | IV | Surgery, chemotherapy | – | – | – | – | – | – | None | 18.9 | 14 | 0 | 9 (MRI) | Lt.M1 |
| 7 | 67/F | Lung adenocarcinoma | IV | Chemotherapy | – | – | + | – | – | + | None | 3.1 | 21 | 0 | 8 (MRI) | Lt.M1 |
| 8 | 36/F | Uterine cervical adenocarcinoma | Recurrence | Surgery, chemoradiotherapy | – | – | – | – | + | - | Edoxaban | 7.7 | 8 | 0 | 9 (MRI) | Rt.M1 |
| 9 | 74/M | Lung small cell carcinoma | III | None | – | – | – | – | – | – | Aspirin | 14.7 | 25 | 3 | 8 (CT) | Lt.M1 |
| 10 | 74/M | Lung adenocarcinoma | Recurrence | Surgery, chemoradiotherapy | + | – | + | – | – | – | Edoxaban | 47.1 | 22 | 3 | 8 (MRI) | Lt.M1 |
| 11 | 49/F | Uterine cervical adenocarcinoma | III | Chemoradiotherapy | + | – | – | – | + | – | Edoxaban | 17.7 | 11 | 0 | 10 (MRI) | Rt.M2 |
| 12 | 78/M | Liver hepatic cell carcinoma | III | Chemotherapy | – | + | – | + | – | – | Warfarin | 3.7 | 30 | 0 | 10 (CT) | Lt.M2 |